| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | APOA1BP |
| Uniprot No | Q8NCW5 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-288aa |
| 氨基酸序列 | MSRLRALLGL GLLVAGSRVP RIKSQTIACR SGPTWWGPQR LNSGGRWDSE VMASTVVKYL SQEEAQAVD QELFNEYQFS VDQLMELAGL SCATAIAKAY PPTSMSRSPP TVLVICGPGN NGGDGLVCA RHLKLFGYEP TIYYPKRPNK PLFTALVTQC QKMDIPFLGE MPAEPMTIDE LYELVVDAI FGFSFKGDVR EPFHSILSVL KGLTVPIASI DIPSGWDVEK GNAGGIQPDL LISLTAPKK SATQFTGRYH YLGGRFVPPA LEKKYQLNLP PYPDTECVYR LQ |
| 预测分子量 | 31 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于APOA1BP重组蛋白的假设性参考文献示例(实际文献需通过学术数据库验证)：
---
1. **标题**: *"Recombinant Expression and Functional Analysis of APOA1BP in HDL Metabolism"*
**作者**: Zhang Y, et al. (2020)
**摘要**: 本研究成功在大肠杆菌中表达并纯化重组APOA1BP蛋白，发现其能增强载脂蛋白A-I(ApoA-I)介导的胆固醇逆向转运，提示其在调节高密度脂蛋白(HDL)功能中的潜在作用。
2. **标题**: *"Structural Insights into APOA1BP and Its Interaction with ApoA-I"*
**作者**: Lee S, Kim M (2018)
**摘要**: 通过X射线晶体学解析重组APOA1BP的三维结构，揭示其与ApoA-I结合的关键结构域，为设计针对脂代谢疾病的药物提供分子基础。
3. **标题**: *"Therapeutic Potential of Recombinant APOA1BP in Atherosclerosis Models"*
**作者**: Brown K, et al. (2021)
**摘要**: 动物实验表明，注射重组APOA1BP可显著减少动脉粥样硬化斑块面积，并改善血脂水平，提示其作为心血管疾病治疗策略的潜力。
4. **标题**: *"APOA1BP Recombinant Protein Enhances Cellular Cholesterol Efflux in Macrophages"*
**作者**: Smith J, et al. (2019)
**摘要**: 体外实验证实重组APOA1BP通过激活ABCA1通路促进巨噬细胞胆固醇流出，为阐明其在抗动脉粥样硬化中的机制提供依据。
---
**注意**：以上文献为模拟示例，实际研究中需通过PubMed、Web of Science等平台检索真实文献。若APOA1BP相关研究较少，建议扩展关键词(如基因别名C4orf14或功能描述)。
**Background of APOA1BP Recombinant Protein**
APOA1BP (Apolipoprotein A-I Binding Protein), also known as AIBP, is a protein involved in lipid metabolism and cellular cholesterol homeostasis. It was initially identified through its interaction with apolipoprotein A-I (ApoA-I), the primary protein component of high-density lipoprotein (HDL), which plays a critical role in reverse cholesterol transport. APOA1BP modulates HDL functionality by influencing ApoA-I-dependent cholesterol efflux, a process essential for removing excess cholesterol from peripheral tissues to the liver for excretion.
Research highlights APOA1BP's role in angiogenesis, inflammation, and mitochondrial function. It regulates endothelial cell signaling, particularly in response to metabolic stress, and has been implicated in pathologies such as atherosclerosis, cancer, and neurodegenerative diseases. Studies suggest that APOA1BP deficiency exacerbates metabolic disorders, while its overexpression may confer protective effects against lipid accumulation and oxidative damage.
Recombinant APOA1BP is produced using genetic engineering techniques, typically expressed in bacterial or mammalian systems to ensure proper folding and post-translational modifications. This purified protein serves as a vital tool for investigating molecular mechanisms underlying lipid metabolism, evaluating therapeutic strategies for cardiovascular diseases, and studying its interactions with ApoA-I or other partners in vitro. Its applications extend to drug screening, biomarker development, and functional assays exploring cellular responses to cholesterol dysregulation.
Overall, APOA1BP recombinant protein is a valuable resource for advancing research into metabolic and inflammatory diseases, offering insights into novel therapeutic targets.
×
